MYC and diffuse large B-cell lymphoma: Lenalidomide showed survival benefit in ABC-DLBCL and may also had an impact on immunomodulation in the EZB-like-MYC+ subtype.7,30,31 In the EZB-like-MYC- DLBCL, NOTCH pathway was activated, suggesting possible effect of NOTCH inhibitors.